Summit Therapeutics Inc. (SMMT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman | -- | -- | 1944 |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director | 657.81k | -- | 1970 |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | -- | -- | 1951 |
| Mr. Bhaskar Anand | Chief Accounting Officer & Head of Finance | -- | -- | 1978 |
| Ms. Abby Guzman Murphy | Head of Human Resources | -- | -- | -- |
| Ms. Divya Chari | Head of Global Clinical Operations | -- | -- | 1968 |
| Mr. Dave Gancarz | Chief Business & Strategy Officer | -- | -- | -- |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology & Inflammation | -- | -- | -- |
| Dr. Fong Clow | Chief Biometrics Officer | -- | -- | -- |
| Ms. Shelley D. Spray | Chief Education & Brand Officer | -- | -- | 1965 |
Summit Therapeutics Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 105
Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Corporate Governance
Upcoming Events
February 18, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC
Summit Therapeutics Inc. Earnings Date